USFDA issues EIR for Granules India’s Gagillapur facility in Hyderabad

13 Jul 2023 Evaluate

US Food & Drug Administration (USFDA) has issued an Establishment Inspection Report (EIR) for Granules India’s Gagillapur facility located in Hyderabad, Telangana, India. This facility, that manufacturers finished dosages (FDs) and Pharmaceutical Formulation Intermediates (PFIs) was inspected by the USFDA as a part of a PAI in January 2023 which resulted in 3 observations during the inspection. 

Granules India is manufacturer and supplier of pharmaceutical products. Its products include active pharmaceutical ingredients (API) like tablets, caplets, rapid release, pharmaceutical, formulation intermediates (PFI) and Finished Dosages (FDs).


Granules India Share Price

399.10 -5.95 (-1.47%)
14-May-2024 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1545.25
Dr. Reddys Lab 5861.00
Cipla 1356.95
Zydus Lifesciences 984.75
Lupin 1635.00
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt.Ltd.